FX.co ★ Anavex Reports Promising EEG Biomarker Results From Phase 2 Study Of ANAVEX 3-71 For Schizophrenia

Anavex Life Sciences Corp. (AVXL) has unveiled encouraging preliminary results from its Phase 2 clinical trial exploring the efficacy of ANAVEX 3-71 in treating schizophrenia, with a focus on electroencephalography (EEG) biomarkers.

Phase 2 study ANAVEX 3-71-SZ-001 Part A involved a multiple ascending dose regimen with 16 participants. These individuals received either an oral placebo, 90 mg of ANAVEX 3-71 daily, or 180 mg of ANAVEX 3-71 daily over a span of 10 days.

Preliminary findings reveal that ANAVEX 3-71 elicited a dose-dependent response on two pivotal EEG biomarkers among schizophrenia patients. Specifically, compared to the placebo group, those treated with ANAVEX 3-71 exhibited enhanced 40 Hz Auditory Steady-State Response (ASSR) Inter Trial Coherence (ITC) and elevated Resting State Alpha Power. The higher dosage group showed the most significant effects, suggesting a dose-dependent pharmacodynamic interaction.

These results substantiate central nervous system (CNS) target engagement and indicate potential therapeutic benefits of ANAVEX 3-71 in managing schizophrenia, according to the company. Additionally, ANAVEX 3-71 was well tolerated, with no serious adverse events reported.

Currently, Part B of the placebo-controlled Phase 2 study is underway, involving a larger cohort and an extended treatment duration. This phase aims to yield more detailed insights into the efficacy and safety profile of ANAVEX 3-71 in schizophrenia. Anavex anticipates that data from Part B will be available in the first half of 2025.